Published in Cancer Res on February 23, 2010
Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun (2013) 4.35
Choline metabolism in malignant transformation. Nat Rev Cancer (2011) 2.85
The human plasma lipidome. N Engl J Med (2011) 2.35
Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis. Proc Natl Acad Sci U S A (2012) 1.41
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med (2013) 1.38
Inhibition of phosphatidylcholine-specific phospholipase C results in loss of mesenchymal traits in metastatic breast cancer cells. Breast Cancer Res (2012) 1.04
MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer. NMR Biomed (2011) 1.03
Tricyclodecan-9-yl-xanthogenate (D609) mechanism of actions: a mini-review of literature. Neurochem Res (2011) 1.03
Human breast cancer tissues contain abundant phosphatidylcholine(36∶1) with high stearoyl-CoA desaturase-1 expression. PLoS One (2013) 1.02
Changes in gene expression and cellular architecture in an ovarian cancer progression model. PLoS One (2011) 1.01
Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer. NMR Biomed (2012) 0.99
Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition. Oncotarget (2010) 0.98
Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer. Br J Cancer (2013) 0.96
Elevated and secreted phospholipase A₂ activities as new potential therapeutic targets in human epithelial ovarian cancer. FASEB J (2012) 0.94
Role of sphingomyelin synthase in controlling the antimicrobial activity of neutrophils against Cryptococcus neoformans. PLoS One (2010) 0.92
In vivo detection of phospholipase C by enzyme-activated near-infrared probes. Bioconjug Chem (2011) 0.92
Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells. NMR Biomed (2011) 0.90
Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts. PLoS One (2013) 0.90
Associations between dietary intake of choline and betaine and lung cancer risk. PLoS One (2013) 0.86
Glucose restriction induces cell death in parental but not in homeodomain-interacting protein kinase 2-depleted RKO colon cancer cells: molecular mechanisms and implications for tumor therapy. Cell Death Dis (2013) 0.86
Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy. Br J Cancer (2013) 0.85
EDI3 links choline metabolism to integrin expression, cell adhesion and spreading. Cell Adh Migr (2014) 0.84
Global metabolic profile identifies choline kinase alpha as a key regulator of glutathione-dependent antioxidant cell defense in ovarian carcinoma. Oncotarget (2015) 0.83
Characterization of choline kinase in human endothelial cells. NMR Biomed (2013) 0.82
Pathway-gene identification for pancreatic cancer survival via doubly regularized Cox regression. BMC Syst Biol (2014) 0.82
Design and synthesis of phospholipase C and A2-activatable near-infrared fluorescent smart probes. Bioconjug Chem (2010) 0.82
Choline metabolism-based molecular diagnosis of cancer: an update. Expert Rev Mol Diagn (2015) 0.81
Overexpression of CHKA contributes to tumor progression and metastasis and predicts poor prognosis in colorectal carcinoma. Oncotarget (2016) 0.81
Acquired resistance to EGFR tyrosine kinase inhibitors alters the metabolism of human head and neck squamous carcinoma cells and xenograft tumours. Br J Cancer (2015) 0.80
Highlights in tumor metabolome research: Choline metabolism influences integrin expression and supports cell attachment. EXCLI J (2014) 0.79
Core-based lipid nanoparticles as a nanoplatform for delivery of near-infrared fluorescent imaging agents. Am J Nucl Med Mol Imaging (2014) 0.79
Activation of Phosphatidylcholine-Specific Phospholipase C in Breast and Ovarian Cancer: Impact on MRS-Detected Choline Metabolic Profile and Perspectives for Targeted Therapy. Front Oncol (2016) 0.79
Phosphatidylcholine metabolic transformation and progression signature as a pharmacodynamic biomarker. Oncotarget (2010) 0.78
The future of imaging: developing the tools for monitoring response to therapy in oncology: the 2009 Sir James MacKenzie Davidson Memorial lecture. Br J Radiol (2010) 0.78
Inhibition of Phosphatidylcholine-Specific Phospholipase C Interferes with Proliferation and Survival of Tumor Initiating Cells in Squamous Cell Carcinoma. PLoS One (2015) 0.78
Phorbol ester stimulates ethanolamine release from the metastatic basal prostate cancer cell line PC3 but not from prostate epithelial cell lines LNCaP and P4E6. Br J Cancer (2014) 0.77
Targeting Phospholipid Metabolism in Cancer. Front Oncol (2016) 0.77
Human prostate cell lines from normal and tumourigenic epithelia differ in the pattern and control of choline lipid headgroups released into the medium on stimulation of protein kinase C. Br J Cancer (2011) 0.76
Choline Metabolism Alteration: A Focus on Ovarian Cancer. Front Oncol (2016) 0.76
Noninvasive phosphorus magnetic resonance spectroscopic imaging predicts outcome to first-line chemotherapy in newly diagnosed patients with diffuse large B-cell lymphoma. Acad Radiol (2013) 0.76
Molecular and functional imaging of invasion and metastasis: windows into the metastatic cascade. Cancer Biomark (2010) 0.76
In vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian Cancer. Front Oncol (2016) 0.76
Choline kinase alpha-Putting the ChoK-hold on tumor metabolism. Prog Lipid Res (2016) 0.76
Distinct plasma lipids profiles of recurrent ovarian cancer by liquid chromatography-mass spectrometry. Oncotarget (2017) 0.75
Phosphatidylcholine-specific phospholipase C inhibition down- regulates CXCR4 expression and interferes with proliferation, invasion and glycolysis in glioma cells. PLoS One (2017) 0.75
Lipidomics analysis of follicular fluid by ESI-MS reveals potential biomarkers for ovarian endometriosis. J Assist Reprod Genet (2015) 0.75
Use of Plasma Metabolomics to Identify Diagnostic Biomarkers for Early Stage Epithelial Ovarian Cancer. J Cancer (2016) 0.75
The action of β-hydroxybutyrate on the growth, metabolism and global histone H3 acetylation of spontaneous mouse mammary tumours: evidence of a β-hydroxybutyrate paradox. Cancer Metab (2017) 0.75
Propolis Reduces Phosphatidylcholine-Specific Phospholipase C Activity and Increases Annexin a7 Level in Oxidized-LDL-Stimulated Human Umbilical Vein Endothelial Cells. Evid Based Complement Alternat Med (2014) 0.75
The Tumor Microenvironment Modulates Choline and Lipid Metabolism. Front Oncol (2016) 0.75
Microfluidic sampling system for tissue analytics. Biomicrofluidics (2015) 0.75
Key Players in Choline Metabolic Reprograming in Triple-Negative Breast Cancer. Front Oncol (2016) 0.75
The nitrobenzoxadiazole derivative MC3181 blocks melanoma invasion and metastasis. Oncotarget (2017) 0.75
Targeting phospholipase D in cancer, infection and neurodegenerative disorders. Nat Rev Drug Discov (2017) 0.75
Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation and in vivo tumor growth in a highly tumorigenic ovarian cancer model. Oncotarget (2017) 0.75
Molecular Effects of Doxorubicin on Choline Metabolism in Breast Cancer. Neoplasia (2017) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res (1999) 3.23
Tumour phospholipid metabolism. NMR Biomed (1999) 2.74
Studies of human tumors by MRS: a review. NMR Biomed (1993) 2.44
Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res (2004) 2.43
Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol (2007) 2.35
Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem (2003) 2.12
Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res (2005) 2.11
Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene (2002) 2.09
Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res (2001) 1.82
In vivo magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng (2005) 1.78
RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res (2005) 1.77
Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int J Cancer (2007) 1.72
Measurement of phospholipase D activity. Anal Biochem (1997) 1.53
Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res (2004) 1.53
Structure and function of choline kinase isoforms in mammalian cells. Prog Lipid Res (2004) 1.49
Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res (2002) 1.40
Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics (2006) 1.38
Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharm (2006) 1.37
Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy: initial results. Radiology (2004) 1.35
Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res (2006) 1.29
Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells. Cancer Res (2007) 1.27
Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft. Cancer Res (2009) 1.27
Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin Cancer Res (2000) 1.24
Phosphatidylcholine-specific phospholipase C activation in epithelial ovarian cancer cells. Cancer Res (2008) 1.19
Preoperative grading of gliomas by using metabolite quantification with high-spatial-resolution proton MR spectroscopic imaging. Radiology (2006) 1.17
Choline kinase: an important target for cancer. Curr Med Chem (2006) 1.16
GDPD5 is a glycerophosphocholine phosphodiesterase that osmotically regulates the osmoprotective organic osmolyte GPC. Proc Natl Acad Sci U S A (2008) 1.12
Characterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway. NMR Biomed (2009) 1.10
A critical role for choline kinase-alpha in the aggressiveness of bladder carcinomas. Oncogene (2009) 1.09
Involvement of phosphatidylcholine-specific phospholipase C in platelet-derived growth factor-induced activation of the mitogen-activated protein kinase pathway in Rat-1 fibroblasts. J Biol Chem (1997) 1.07
Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate. Nucl Med Biol (2004) 1.02
Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells. Int J Cancer (1997) 1.02
Phosphatidylcholine-specific phospholipase C in mitogen-stimulated fibroblasts. Exp Cell Res (2004) 1.01
Role of phospholipase D in agonist-stimulated lysophosphatidic acid synthesis by ovarian cancer cells. J Lipid Res (2003) 1.00
Detection of phosphatidylcholine-specific phospholipase C in NIH-3T3 fibroblasts and their H-ras transformants: NMR and immunochemical studies. Anticancer Res (1996) 0.98
CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma. Clin Cancer Res (2004) 0.98
Determination of the kinetic parameters for phospholipase C (Bacillus cereus) on different phospholipid substrates using a chromogenic assay based on the quantitation of inorganic phosphate. Anal Biochem (1997) 0.97
Intestinal alkaline sphingomyelinase hydrolyses and inactivates platelet-activating factor by a phospholipase C activity. Biochem J (2006) 0.95
Pharmacodynamic markers for choline kinase down-regulation in breast cancer cells. Neoplasia (2009) 0.94
Molecular and functional characterization of choline transporter in human colon carcinoma HT-29 cells. Arch Biochem Biophys (2008) 0.94
Loss of p53 function in colon cancer cells results in increased phosphocholine and total choline. Mol Imaging (2004) 0.93
Choline transporter as a novel target for molecular imaging of cancer. Mol Imaging (2006) 0.91
Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET. J Nucl Med (2003) 0.89
Phosphatidylcholine-specific phospholipase C and ROS were involved in chicken blastodisc differentiation to vascular endothelial cells. J Cell Biochem (2007) 0.81
Measurements of phospholipases A2, C, and D (PLA2, PLC, and PLD). In vitro microassays, analysis of enzyme isoforms, and intact-cell assays. Methods Mol Biol (2003) 0.80
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Identification and characterization of enhancers controlling the inflammatory gene expression program in macrophages. Immunity (2010) 6.48
HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell (2007) 4.81
Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet (2012) 3.08
MRI of the tumor microenvironment. J Magn Reson Imaging (2002) 2.87
Choline metabolism in malignant transformation. Nat Rev Cancer (2011) 2.85
Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res (2004) 2.43
Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. Radiology (2007) 2.22
Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem (2003) 2.12
Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res (2005) 2.11
Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol (2011) 2.09
Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res (2003) 2.05
Four enzymes cooperate to displace histone H1 during the first minute of hormonal gene activation. Genes Dev (2011) 1.97
Natural D-glucose as a biodegradable MRI contrast agent for detecting cancer. Magn Reson Med (2012) 1.84
SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood (2013) 1.81
RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res (2005) 1.77
MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med (2003) 1.76
Extracellular acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia (2004) 1.70
Scale-free structural organization of oxygen interstitials in La(2)CuO(4+y). Nature (2010) 1.69
pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer (2010) 1.58
CCAAT/enhancer binding protein alpha (C/EBP(alpha))-induced transdifferentiation of pre-B cells into macrophages involves no overt retrodifferentiation. Proc Natl Acad Sci U S A (2011) 1.57
Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diagn (2006) 1.54
Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model. Cancer Res (2008) 1.52
The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res (2006) 1.50
Epicardial ganglionated plexus stimulation decreases postoperative inflammatory response in humans. Heart Rhythm (2012) 1.46
A prospective, randomized evaluation of the effects of epidural needle rotation on the distribution of epidural block. Anesth Analg (2004) 1.44
Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. Int J Biochem Cell Biol (2009) 1.43
Characterizing vascular parameters in hypoxic regions: a combined magnetic resonance and optical imaging study of a human prostate cancer model. Cancer Res (2006) 1.41
Evolution and control of oxygen order in a cuprate superconductor. Nat Mater (2011) 1.41
Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results. Invest Radiol (2011) 1.39
The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle (2009) 1.38
M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int J Cancer (2006) 1.38
Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharm (2006) 1.37
Nucleosome-driven transcription factor binding and gene regulation. Mol Cell (2012) 1.34
MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol (2014) 1.33
The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. Cancer Res (2008) 1.33
Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography. Cancer Res (2010) 1.32
Self-assembled three dimensional radio frequency (RF) shielded containers for cell encapsulation. Biomed Microdevices (2005) 1.28
Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells. Cancer Res (2007) 1.27
Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft. Cancer Res (2009) 1.27
Immune surveillance properties of human NK cell-derived exosomes. J Immunol (2012) 1.26
The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res (2007) 1.25
Hypoxia regulates CD44 and its variant isoforms through HIF-1α in triple negative breast cancer. PLoS One (2012) 1.25
CDK2-dependent activation of PARP-1 is required for hormonal gene regulation in breast cancer cells. Genes Dev (2012) 1.24
The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proc Natl Acad Sci U S A (2011) 1.24
UQCRH gene encoding mitochondrial Hinge protein is interrupted by a translocation in a soft-tissue sarcoma and epigenetically inactivated in some cancer cell lines. Oncogene (2003) 1.22
Metabolic tumor imaging using magnetic resonance spectroscopy. Semin Oncol (2011) 1.22
Metabolomics of cancer. Methods Mol Biol (2009) 1.21
Phosphatidylcholine-specific phospholipase C activation in epithelial ovarian cancer cells. Cancer Res (2008) 1.19
Magnetic resonance imaging of cell surface receptors using targeted contrast agents. Curr Pharm Biotechnol (2004) 1.17
AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets. PLoS Genet (2008) 1.17
Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene (2004) 1.16
Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells. Breast Cancer Res (2010) 1.16
Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res (2008) 1.16
Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res (2008) 1.16
Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer. Int J Biochem Cell Biol (2009) 1.16
Characterizing extravascular fluid transport of macromolecules in the tumor interstitium by magnetic resonance imaging. Cancer Res (2005) 1.15
Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget (2011) 1.14
Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells. Mol Cancer Res (2007) 1.14
MR evaluation of response to targeted treatment in cancer cells. NMR Biomed (2011) 1.14
PAMAM dendrimer-based contrast agents for MR imaging of Her-2/neu receptors by a three-step pretargeting approach. Magn Reson Med (2008) 1.13
Tumor initiating cells: development and critical characterization of a model derived from the A431 carcinoma cell line forming spheres in suspension. Cell Cycle (2010) 1.13
Hypoxic tumor microenvironments reduce collagen I fiber density. Neoplasia (2010) 1.12
Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts. Neoplasia (2009) 1.10
Combined dynamic contrast enhanced breast MR and proton spectroscopic imaging: a feasibility study. J Magn Reson Imaging (2005) 1.08
Collagen I fiber density increases in lymph node positive breast cancers: pilot study. J Biomed Opt (2012) 1.08
DNA damage-induced cell cycle regulation and function of novel Chk2 phosphoresidues. Mol Cell Biol (2006) 1.07
MRI screening of women with hereditary predisposition to breast cancer: diagnostic performance and survival analysis. Breast Cancer Res Treat (2014) 1.07
Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection? Eur Radiol (2006) 1.07
Magnetic resonance spectroscopy in metabolic and molecular imaging and diagnosis of cancer. Chem Rev (2010) 1.06
The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Res (2003) 1.06
Multimodal mass spectrometric imaging of small molecules reveals distinct spatio-molecular signatures in differentially metastatic breast tumor models. Cancer Res (2010) 1.06
Sciatica: treatment with intradiscal and intraforaminal injections of steroid and oxygen-ozone versus steroid only. Radiology (2007) 1.05
Optimum inhomogeneity of local lattice distortions in La2CuO(4+y). Proc Natl Acad Sci U S A (2012) 1.05